Patent classifications
C12N9/0069
Luciferase sequences utilizing infrared-emitting substrates to produce enhanced luminescence
Provided herein are isolated polynucleotide encoding modified click beetle luciferase polypeptides that have enhanced luminescence and longer wavelength near-infrared signals. The disclosure also relates to near-infrared bioluminescence systems that include said modified click beetle luciferase polypeptides and novel luciferin derivatives, as well as methods of using said modified click beetle luciferase polypeptides and bioluminescence systems.
Of herbicide tolerance to 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors by down-regulation of HPPD expression in soybean
A method for conferring tolerance to a 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor herbicide in a plant includes reducing expression of at least one HPPD enzyme in the plant.
BIOSYNTHESIS OF VANILLIN FROM ISOEUGENOL
The present invention relates to the production of vanillin via the bioconversion of isoeugenol. The bioconversion can be mediated in a cellular system (e.g., an Escherichia coli bacterium), or in an enzymatic reaction mixture without a cellular system.
BIOSYNTHESIS OF VANILLIN FROM ISOEUGENOL
The present invention relates to the production of vanillin via the bioconversion of isoeugenol. The bioconversion can be mediated in a cellular system (e.g., an Escherichia coli bacterium), or in an enzymatic reaction mixture without a cellular system.
CLEANING COMPOSITION COMPRISING AN ALPHA-DIOXYGENASE
Cleaning compositions having fatty acid alpha-dioxygenases and methods of using said compositions to provide a benefit by converting long chain fatty acids present in soils into 2-hydroperoxy fatty acids or terminal aldehydes.
PATHOGEN DETECTION METHOD AND APPARATUS
A pathogen detection method includes forming nanoparticles, extracting adenosine triphosphate (ATP) by causing the nanoparticles to collide with pathogens, collecting the pathogens having collided with the nanoparticles, and detecting a light-emitting reaction formed by a reaction with the ATP.
NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS
Compounds are provided having the following structure:
##STR00001##
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1, R.sup.2, R.sup.3, L.sup.1, L.sup.2, G.sup.1, G.sup.2 and G.sup.3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Novel Cell-Based Assay for Determining Activity in the Retinoblastoma Pathway
Disclosed are methods of determining activity of CDK4 and CDK6 variants upon exposure to CDK inhibitors, methods for determining activity of a Rb variant, methods for determining the activity of a p16 variant in a cell, and methods for determining the sensitivity of a CDK4 variant or a CDK6 variant to p16 in a cell. Stable cell lines for determining activity of CDK4 variants, CDK6 variants, Rb variants, and p16 variants are also disclosed.
Method for synthetic genes
The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a GC content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a GC content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes.
LUCIFERASE VARIANT
In one embodiment, an object of the present invention is to provide a firefly luciferase having improved thermostability. In one embodiment, the present invention relates to a luciferase mutant having improved thermostability that is a mutant of firefly luciferase comprising an amino acid sequence in which the amino acid residue at the position corresponding to position 393 of SEQ ID NO 1 is substituted, a polynucleotide encoding the luciferase mutant, and a production method of the luciferase mutant.